Apremilast for the management of moderate to severe plaque psoriasis
Apremilast for the management of moderate to severe plaque psoriasis
复制标题
DOI：
10.1080/17512433.2017.1293519
复制
发表时间：
2017-01-01
影响因子：
4.4
通讯作者：
Alikhan, Ali
中科院分区：
文献类型：
--
作者：
Vangipuram, Ramya;Alikhan, Ali
简介：银屑病是一种慢性炎症性皮肤病，其特征是伸肌表面、头皮和背部有红斑。目前治疗牛皮癣的方法受到给药途径、副作用和成本的限制。阿普米司特是第一种口服磷酸二酯酶抑制剂，被批准用于中到重度斑块型牛皮癣。它是一种磷酸二酯酶-4的小分子抑制剂，可降低与银屑病相关的炎症活动。内容包括：该药的药理作用、作用机制、关键临床试验结果及其在银屑病治疗中的应用。目前批准的治疗方法也进行了讨论。专家评论：apremilast的优势包括方便的口服给药和剂量，良好的安全性和耐受性，以及对中到重度斑块型银屑病的显著疗效。
Introduction: Psoriasis is a chronic inflammatory skin disease characterized by erythematous plaques on extensor surfaces, scalp, and back. Current therapies for psoriasis are limited by route of administration, side effects, and cost. Apremilast is the first oral phosphodiesterase inhibitor approved for moderate-to-severe plaque psoriasis. It is a small molecule inhibitor of phosphodiesterase-4, and decreases the inflammatory activity associated with psoriasis.Areas covered: This review will discuss the pharmacology of apremilast, mechanism of action, results from key clinical trials, and its use in managing psoriasis. Currently approved treatments are also discussed.Expert commentary: The advantages of apremilast include convenient oral administration and dosing, a favorable safety and tolerability profile, and significant efficacy in moderate-to-severe plaque psoriasis.